Risk Stratification and Outcomes of Management in Egyptian Patients with Fistulizing Crohn's Disease | ||
| African Journal of Gastroenterology and Hepatology | ||
| Volume 8, Issue 1, 2025, Pages 175-200 PDF (599.24 K) | ||
| Document Type: Original Clinical | ||
| DOI: 10.21608/ajgh.2025.394851.1085 | ||
| Authors | ||
| Mostafa Elfors* 1; Emad Awad1; Shereen Saleh1; Khaled Hamdy1; Hany Shehab2; Hedy A. Badary2; Ahmed Farrag2; Amr Yehia1; Hager El Essawy1 | ||
| 1Internal Medicine Department, Hepatology and GIT Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||
| 2Integrated Clinical and Research Center for Intestinal Disorders (ICRID), Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. | ||
| Abstract | ||
| Background: Crohn’s disease (CD) is a chronic, relapsing inflammatory condition of uncertain origin that can affect any segment of the gastrointestinal tract in a transmural pattern, often resulting in complications such as fistulae or perforation. Although its prevalence appears to be rising in Egypt, precise epidemiological figures are lacking. The present study was designed to identify risk factors associated with fistulizing CD and to examine treatment outcomes in affected Egyptian patients. Methods: The present retrospective–prospective cohort study comprised 90 Egyptian individuals with Crohn’s disease, divided into a fistulizing group (n = 45) and a non-fistulizing group (n = 45). The clinical features, risk factors, and treatment outcomes were evaluated. The clinical, radiographic, and colonoscopic examinations were also performed and assessed before and after treatment. Results: Male sex and smoking were more prevalent but not significant among cases with fistulizing CD. Enteroenteric fistulas were the most common subtype, while infliximab therapy and surgical intervention were the most frequent treatment strategies. The use of non-steroidal anti-inflammatory drugs (NSAIDs) was significantly higher in the fistula group. Both groups showed significant improvement following treatment, as indicated by the simplified endoscopic activity score for Crohn’s disease (SES-CD) and the Crohn’s Disease Activity Index (CDAI), with the fistula group demonstrating a more substantial response. In conclusion, this study identifies NSAID use as a significant risk factor for the development of fistulizing Crohn’s disease. It reinforces the clinical utility of CDAI scores in evaluating disease activity and monitoring treatment outcomes. | ||
| Keywords | ||
| Crohn's disease; fistulizing Crohn's disease; Outcomes of Management; CDAI scores; Colonoscopy; Endoscopic Score for Crohn’s Disease; Risk factors; NSAID; Infliximab; Adalimumab | ||
|
Supplementary Files
|
||
|
Statistics Article View: 4 PDF Download: 2 |
||
